DJIA 17,356.87 288.00 1.69%
NASDAQ 4,644.31 96.48 2.12%
S&P 500 2,012.89 40.15 2.04%
market minute promo

0.24 0.01 (2.13%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

HEB $0.24 2.13%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.24
Previous Close $0.24
Daily Range $0.24 - $0.25
52-Week Range $0.22 - $0.55
Market Cap $48.0M
P/E Ratio -2.61
Dividend (Yield) $0.00 (0.0%)
Volume 632,961
Average Daily Volume 824,274
Current FY EPS $0.00

Sector

Healthcare

Industry

Drugs

Hemispherx BioPharma, Inc. (HEB) Description

A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Website: http://www.hemispherx.net/

News & Commentary Rss Feed

NeoStem CFO Taking on New Role at Company

Robert Dickey hired to be CFO.

Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibi

Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors

Biotech Weekly: Everything You Want To Know About Small Cap Biotech Cult Stocks

Hemispherx Biopharma's Ebola Lawyer: A Detailed Breakdown

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

Ebola Hits NYC: Time To Panic

Hemispherx Joins The Ebola Game

Hemispherx BioPharma: Any Pops On Ebola News Are The Time To Sell

Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC As Governmental

Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC As Governmental Counsel In Fight Against Ebola

Ebola Patient Eric Duncan Dies; Related Stocks Fall On News

Ebola Outbreak Puts the Spotlight on 10 Biotech Companies

See More HEB News...

HEB's Top Competitors

HEB $0.24 (2.13%)
Current stock: HEB
AMGN $163.48 (2.53%)
Current stock: AMGN
GILD $102.40 (1.93%)
Current stock: GILD
BIIB $332.89 (2.39%)
Current stock: BIIB